Closing the case of APOE in multiple sclerosis: No association with disease risk in over 29 000 subjects

CM Lill; T Liu; BMM Schjeide; JT Roehr; DA Akkad; V Damotte; A Alcina; MA Ortiz; R Arroyo; AL de Lapuente; P Blaschke; A Winkelmann; LA Gerdes; F Luessi; O Fernadez; G Izquierdo; A Antigüedad; S Hoffjan; I Cournu-Rebeix; S Gromöller; H Faber; M Liebsch; E Meissner; C Chanvillard; E Touze; F Pico; P Corcia; T Dörner; E Steinhagen-Thiessen; L Baeckman; HR Heekeren; SC Li; U Lindenberger; A Chan; HP Hartung; O Aktas; P Lohse; T Kümpfel; C Kubisch; JT Epplen; UK Zettl; B Fontaine; K Vandenbroeck; F Matesanz; E Urcelay; L Bertram; F Zipp; M Bahlo; DR Booth; SA Broadley; MA Brown; BL Browning; SR Browning; H Butzkueven; WM Carroll; MB Cox; C Chapman; G Clarke; P Danoy; K Drysdale; J Field; SJ Foote; JM Greer; LR Griffiths; CJ Jensen; LJ Johnson; AG Kermode; RN Heard; TJ Kilpatrick; J Lechner-Scott; M Marriott; D Mason; P Moscato; MP Pender; VM Perreau; JP Rubio; RJ Scott; M Slee; J Stankovich; GJ Stewart; L Tajouri; BV Taylor; J Wiley; EJ Wilkins

Journal article

Closing the case of APOE in multiple sclerosis: No association with disease risk in over 29 000 subjects

CM Lill, T Liu, BMM Schjeide, JT Roehr, DA Akkad, V Damotte, A Alcina, MA Ortiz, R Arroyo, AL de Lapuente, P Blaschke, A Winkelmann, LA Gerdes, F Luessi, O Fernadez, G Izquierdo, A Antigüedad, S Hoffjan, I Cournu-Rebeix, S Gromöller Show all

Journal of Medical Genetics | Published : 2012

DOI: 10.1136/jmedgenet-2012-101175

Abstract

Background: Single nucleotide polymorphisms (SNPs) rs429358 (ε4) and rs7412 (ε2), both invoking changes in the amino-acid sequence of the apolipoprotein E (APOE) gene, have previously been tested for association with multiple sclerosis (MS) risk. However, none of these studies was sufficiently powered to detect modest effect sizes at acceptable type-I error rates. As both SNPs are only imperfectly captured on commonly used microarray genotyping platforms, their evaluation in the context of genome-wide association studies has been hindered until recently. Methods: We genotyped 12 740 subjects hitherto not studied for their APOE status, imputed raw genotype data from 8739 subjects from five in..

View full abstract

University of Melbourne Researchers

Melanie Bahlo Author

Judith Field Author

Trevor Kilpatrick Author

Vicky Perreau Author

Grants

Awarded by European Commission

Funding Acknowledgements

This project was funded by grants from the German Ministry for Education and Research (BMBF) and German Research Foundation (DFG; to FZ), the BMBF and the Cure Alzheimer's Fund (to LB (Berlin)), the Walter- and Ilse-Rose-Stiftung (to H-PH and OA), the BMBF (grant NBL3 to UKZ; grant 01UW0808 to UL, and ES-T), and the Innovation Fund of the Max Planck Society (M.FE.A.BILD0002 to UL). This project was supported by INSERM, ARSEP, AFM and GIS-IBISA. CML was supported by the Fidelity Biosciences Research Initiative. CC was supported by the European Framework FP7/2007-2013 (no 212877 UEPHA*MS). LB (Stockholm) was supported by the Swedish Research Council (Grant 521-2007-2892), Swedish Brain Power, and an Alexander von Humboldt Research Award. AA [Granada] and FM were supported by the Ministerio de Ciencia e Innovacion (MCINN)-Fondos Europeos de Desarrollo Regional (FEDER) [grant number SAF2009-11491] and EU by the Instituto de Salud Carlos III, FIS10/1985. Dr LA Gerdes reports to have received travel expenses and personal compensation from Merck Serono, Teva Pharmaceutical Industries, Bayer Schering Pharma, Novartis, and Biogen Idec. Dr T Kumpfel reports to have received travel expenses and personal compensations from Bayer Schering Pharmacy, Teva, Merck-Serono, Novartis, Sanofi-Aventis and Biogen-Idec as well as grant support from Bayer-Schering AG. None of the other authors reports any disclosures.